Wai Yuen Tong Medicine Holdings Limited (HK:0897)
:0897
Want to see HK:0897 full AI Analyst Report?
0897 Stock Chart & Stats
HK$0.36
>-HK$0.01(-1.67%)
At close: 4:00 PM EST
HK$0.36
>-HK$0.01(-1.67%)
Day’s Range― - ―
52-Week RangeHK$0.29 - HK$0.51
Previous CloseN/A
Volume490.00K
Average Volume (3M)632.59K
Market Cap
HK$384.46M
Enterprise ValueHK$548.06M
Total Cash (Recent Filing)HK$135.68M
Total Debt (Recent Filing)HK$301.48M
Price to Earnings (P/E)43.6
Beta0.10
Next Earnings
Jun 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.5%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,114,382,900
10 Day Avg. Volume746,291
30 Day Avg. Volume632,591
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)0.34
Price to Sales (P/S)0.54
P/FCF Ratio5.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-channel Revenue ModelA dual retail and distribution model provides structural resilience: retail drives consumer brand exposure and margins, while distribution supplies steady B2B volume. Over months this diversification smooths demand swings, aids scale purchasing, and supports margin retention across channels.
Stable Gross Profit MarginsConsistently stable gross margins point to durable procurement, manufacturing, or product mix advantages. Sustained gross margin stability helps absorb SG&A variability, underpins long-run cash conversion potential, and provides a buffer for reinvestment or pricing pressure in the core Chinese medicine business.
Manageable LeverageRelatively low leverage offers financial flexibility over the medium term: it lowers bankruptcy risk, preserves capacity for targeted capital expenditures or acquisitions, and reduces refinancing pressure during tighter liquidity periods, supporting sustained operations and strategic initiatives.
Bears Say
Weak Cash GenerationNegative free cash flow growth and weak conversion of income into cash are structural concerns: they limit the company's ability to self-fund capex, pay consistent dividends, or build reserves. Over months this raises reliance on external financing and constrains strategic flexibility.
Low Profitability MetricsPersistently low net margins indicate underlying cost or operating inefficiencies that erode returns. Over time this limits retained earnings, depresses return on equity, and reduces the company's capacity to reinvest in growth or brand-building, hindering sustainable shareholder value creation.
Volatile Revenue GrowthIrregular top-line growth undermines predictability for inventory, staffing, and procurement decisions. Structural volatility complicates forecasting and capex planning, can magnify working capital swings, and makes it harder to demonstrate durable demand trends to partners and lenders over the coming months.
Wai Yuen Tong Medicine Holdings Limited News
0897 FAQ
What was Wai Yuen Tong Medicine Holdings Limited’s price range in the past 12 months?
Wai Yuen Tong Medicine Holdings Limited lowest stock price was HK$0.28 and its highest was HK$0.51 in the past 12 months.
What is Wai Yuen Tong Medicine Holdings Limited’s market cap?
Wai Yuen Tong Medicine Holdings Limited’s market cap is HK$384.46M.
When is Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date?
Wai Yuen Tong Medicine Holdings Limited’s upcoming earnings report date is Jun 30, 2026 which is in 62 days.
How were Wai Yuen Tong Medicine Holdings Limited’s earnings last quarter?
Wai Yuen Tong Medicine Holdings Limited released its earnings results on Nov 24, 2025. The company reported HK$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.002.
Is Wai Yuen Tong Medicine Holdings Limited overvalued?
According to Wall Street analysts Wai Yuen Tong Medicine Holdings Limited’s price is currently Overvalued.
Does Wai Yuen Tong Medicine Holdings Limited pay dividends?
Wai Yuen Tong Medicine Holdings Limited pays a Notavailable dividend of HK$0.03 which represents an annual dividend yield of 7.5%. See more information on Wai Yuen Tong Medicine Holdings Limited dividends here
What is Wai Yuen Tong Medicine Holdings Limited’s EPS estimate?
Wai Yuen Tong Medicine Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wai Yuen Tong Medicine Holdings Limited have?
Wai Yuen Tong Medicine Holdings Limited has 1,114,382,900 shares outstanding.
What happened to Wai Yuen Tong Medicine Holdings Limited’s price movement after its last earnings report?
Wai Yuen Tong Medicine Holdings Limited reported an EPS of HK$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wai Yuen Tong Medicine Holdings Limited?
Currently, no hedge funds are holding shares in HK:0897
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wai Yuen Tong Medicine Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.19%
12-Months-Change
Fundamentals
Return on Equity
-1.17%
Trailing 12-Months
Asset Growth
-4.76%
Trailing 12-Months
Company Description
Wai Yuen Tong Medicine Holdings Limited
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicines, Western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally. The company offers Chinese medicines and health food products under the Wai Yuen Tong brand name; and Western pharmaceutical and personal care products under the Madame Pearl's and Pearl's brands. It also engages in the investment, holding, and selling of properties; provision of financial services; and agricultural produce exchange market operation. As of March 31, 2022, the company operated 63 retail stores in Hong Kong. The company was founded in 1897 and is headquartered in Kowloon Bay, Hong Kong. Wai Yuen Tong Medicine Holdings Limited is a subsidiary of Rich Time Strategy Limited.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―
Zhongzhi Pharmaceutical Holdings Limited
―